Eoganacht ... You have the proper comprehension of the role of Dr. Kamat. His role is to advise on treatments that have clear data to comment on. So far, this not our case yet. Not to speculate on trends that are not clear enough.
Our time will come, if data dominates. And 450-days on our first 25 patients should do it. But we're not there yet.
Eoganacht - (7/12/2022 11:38:57 AM)
RE:RE:RE:RE:RE:Theralase Is still Flying Under the Radar
Dr. Kamat can say whatever he wants to say whenever he wants to say it. But when he is talking to another urological oncologist about what is going to be relevant to the bladder cancer patient and physician in the next few months, it should not come as a surprise if he confines his remarks to drugs that have applied to the FDA for approval and could be available for use in the very near future.
Dr. Kamat is not a stock pumper. He is a physician whose focus is helping patients who are sick right now. In early 2023 when Theralase has applied for BTD and AA and may actually be about to be available to bladder cancer patients, I expect Dr. Kamat will have a lot to say. All IMHO.
Yajne wrote:Sooo, I hear that Dr Kamat will not (or cannot) comment on a trail until that trial is complete. I don't believe that is true, I remember Dr Kamat commenting on various trials even while they were still in progress, although I can't find the specific link. Unless somebody can prove otherwise, I continue to believe that Dr Kamat mentioned other 'in progress trials'. This is important because just his mention could influence urologists in one direction versus another... and that's exremely important for recruting patients for a trial. Don't care what the braniacs such as Bencro (RIP- new alias) has to say about this, I don't believe that Dr.Kamat has been impartial oin potential NIMBC treatment solutions. He knew the safety profile of TLD1433 and impressive results that terminated Ph1b early so that should have allowed him to comment on the Phase2 trial for TLD1433. All IMHO of course